Table 1 Baseline characteristics of patients with stage T3-4N1 NPC before and after match

Sex

0.927

0.644

 Male

103 (75.7%)

111 (76.0%)

63 (74.1%)

60 (70.6%)

 Female

32 (23.5%)

35 (24.0%)

21 (24.7%)

25 (29.4%)

 Age (years)

Median: 45,

range: 21–73

Median: 45,

range: 23–73

0.795

Median: 41,

range: 22–73

Median: 44,

range: 23–66

0.287

Smoking history

0.660

0.858

 No

88 (64.7%)

98 (67.1%)

64 (75.3%)

65 (76.5%)

 Yes

48 (35.3%)

48 (32.9%)

21 (24.7%)

20 (23.5%)

Alcohol history

0.181

0.073

 No

117 (86.0%)

133 (91.1%)

76 (89.4%)

82 (96.5%)

 Yes

19 (14.0%)

13 (8.9%)

9 (10.6%)

3 (3.5%)

Family of cancer

0.177

0.093

 No

103 (75.7%)

100 (68.5%)

65 (76.5%)

55 (64.7%)

 Yes

33 (24.3%)

46 (31.5%)

20 (23.5%)

30 (35.3%)

T classification

< 0.001

1.000

 T3

67 (49.3%)

128 (87.7%)

67 (78.8%)

67 (78.8%)

 T4

69 (50.7%)

18 (12.3%)

18 (21.2%)

18 (21.2%)

Lymph node diameter (mm, maximum)

Median: 14.5,

range: 4–36

Median: 14,

range: 4–41

0.155

Median: 16,

range: 5–36

Median: 12,

range: 4–41

0.138

PLNC

0.181

 Negative

104 (76.5%)

121 (82.9%)

67 (78.8%)

70 (82.4%)

 Positive

32 (23.5%)

25 (17.1%)

18 (21.2%)

15 (17.6%)

0.562

Cervical lymph node

0.442

0.497

 No

41 (30.1%)

38 (26.0%)

22 (25.9%)

26 (30.6%)

 Yes

95 (69.9%)

108 (74.0%)

63 (74.1%)

59 (69.4%)

EBV DNA (copy/ml)

0.013

1.000

  ≤ 2000

59 (43.4%)

85 (58.2%)

39 (45.9%)

39 (45.9%)

  > 2000

77 (56.6%)

61 (41.8%)

46 (54.1%)

46 (54.1%)

HGB, g/L

0.918

0.683

  < 113

3 (2.2%)

1 (0.7%)

3 (3.5%)

1 (1.2%)

 113–151

87 (64.0%)

98 (67.1%)

51 (60.0%)

57 (67.1%)

  ≥ 151

46 (33.8%)

47 (32.2%)

31 (36.5%)

27 (31.8%)

CRP, g/ml

0.057

0.104

  < 1.0

45 (33.1%)

59 (40.4%)

28 (32.9%)

39 (45.9%)

 1.0–3.0

44 (32.4%)

53 (36.3%)

30 (35.3%)

25 (29.4%)

  ≥ 3.0

47 (34.6%)

34 (23.3%)

27 (31.8%)

21 (24.7%)

LDH, U/L

0.349

0.756

  < 245

127 (93.4%)

140 (95.9%)

79 (92.9%)

80 (94.1%)

  ≥ 245

9 (6.6%)

6 (4.1%)

6 (7.1%)

5 (5.9%)